As CML Drugs Improve, Earlier Surrogate Outcome Markers Needed

As patients and physicians gain experience with a second generation of relatively effective therapies for chronic myeloid leukemia, there is increasing need to quickly understand who will fare best with these drugs.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news